Ep. 76 - FDA Inflection Point: Steve Usdin on Biopharma during Trump 2.0

All presidential transitions with a change of party come with disruption and threats as well as opportunities. But this one, in particular with regard to the implications for FDA, is different from all those Steve Usdin has been covering in his 30-year tenure as Washington editor at BioCentury.
In particular, this is an inflection point for the agency that currently serves as the global gold standard for drug regulation, said Usdin on a special edition of The BioCentury Show covering the ramifications for the biopharma industry of the second Trump administration. Usdin has recently outlined the threats and opportunities that the new era presents, and he elaborated further on those in a discussion with Editor in Chief Simone Fishburn.

View full story: https://www.biocentury.com/article/654798

#biotech #biopharma #pharma #lifescience #politics #policy #fda #ftc #biosecure #ira

00:00 - Introduction
05:06 - Inflection Point at FDA
14:10 - Changes at the FTC
16:43 - China, Biosecure
21:30 - The IRA